By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Emergent BioSolutions 

2273 Research Boulevard
Suite 400
Rockville  Maryland  20850  U.S.A.
Phone: 301-795-1800 Fax: 301-795-1899


SEARCH JOBS
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.


Key Statistics


Email:
Ownership: Public

Web Site: Emergent BioSolutions
Employees:
Symbol: EBS
 









Company News
Emergent BioSolutions (EBS) To Webcast Presentation At Credit Suisse 2014 Healthcare Conference 10/20/2014 7:19:51 AM
Prophylix Pharma Signs Manufacturing Agreement With Emergent BioSolutions (EBS) 10/14/2014 2:26:16 PM
Emergent BioSolutions (EBS) To Release Third Quarter 2014 Financial Results And Conduct A Conference Call On November 6, 2014 10/9/2014 10:41:40 AM
Emergent BioSolutions (EBS) Initiates Final Pivotal Study To Support Licensure Of BioThrax At Large Scale 9/23/2014 11:30:03 AM
Emergent BioSolutions (EBS) Awarded $29 Million Contract To Develop A Dry Formulation Of Nuthrax 9/9/2014 11:02:37 AM
Emergent BioSolutions (EBS) Awarded Contract To Develop A Dry Formulation Of Nuthrax, A Next Generation Anthrax Vaccine 9/8/2014 12:35:37 PM
Emergent BioSolutions (EBS), MorphoSys AG Strike Prostate Cancer Pact Worth $183 Million 8/20/2014 6:14:28 AM
U.S. Government Exercises Contract Options Valued At $18.9 Million For Emergent BioSolutions (EBS)' Vaccinia Immune Globulin Intravenous Program 8/8/2014 9:45:15 AM
Emergent BioSolutions (EBS) Reports Financial Results For Second Quarter And First Six Months Of 2014 8/8/2014 9:10:30 AM
Emergent BioSolutions (EBS) Submits Biologics License Application To FDA For Anthrax Immune Globulin Intravenous (Human) 8/7/2014 10:04:54 AM
12345678910...
//-->